SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-140076
Filing Date
2023-05-10
Accepted
2023-05-10 08:05:00
Documents
17
Period of Report
2023-05-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d436727d8k.htm   iXBRL 8-K 55495
2 EX-2.1 d436727dex21.htm EX-2.1 499031
3 EX-3.1 d436727dex31.htm EX-3.1 127527
4 EX-99.1 d436727dex991.htm EX-99.1 82615
5 EX-99.2 d436727dex992.htm EX-99.2 16585
9 GRAPHIC g436727g0510112229502.jpg GRAPHIC 3164
  Complete submission text file 0001193125-23-140076.txt   1102409

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ctic-20230510.xsd EX-101.SCH 2853
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctic-20230510_lab.xml EX-101.LAB 18739
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctic-20230510_pre.xml EX-101.PRE 11709
11 EXTRACTED XBRL INSTANCE DOCUMENT d436727d8k_htm.xml XML 3641
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 23904417
SIC: 2834 Pharmaceutical Preparations